Bionik Laboratories Corp Stock Today
BNKL Stock | USD 0.0001 0.00 0.00% |
PerformanceOK
| Odds Of DistressQuite High
|
Bionik Laboratories is selling for 1.0E-4 as of the 22nd of March 2025. This is a No Change since the beginning of the trading day. The stock's lowest day price was 1.0E-4. Bionik Laboratories has more than 67 % chance of experiencing financial distress in the next few years of operation. However, it had a very ok returns during the last 90 days. The performance scores are derived for the period starting the 22nd of December 2024 and ending today, the 22nd of March 2025. Click here to learn more.
Bionik Laboratories Corp., a robotics company, engages in designing, developing, and commercializing physical rehabilitation technologies, prosthetics, and assisted robotic products. Bionik Laboratories Corp. was incorporated in 2010 and is headquartered in Watertown, Massachusetts. The company has 6.88 M outstanding shares. More on Bionik Laboratories Corp
Moving against Bionik Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Bionik Pink Sheet Highlights
Business Concentration | Health Care, Health Care Equipment & Supplies, Medical Care Facilities, Healthcare (View all Sectors) |
Bionik Laboratories Corp [BNKL] is a Pink Sheet which is traded between brokers over the counter. The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.27 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Bionik Laboratories's market, we take the total number of its shares issued and multiply it by Bionik Laboratories's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Bionik Laboratories Corp conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 6.88 M outstanding shares.
Bionik Laboratories Corp currently holds about 1.33 M in cash with (4.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.19, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Bionik Laboratories Probability Of Bankruptcy
Ownership AllocationBionik Laboratories Corp shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 61.64 percent of Bionik Laboratories Corp outstanding shares that are owned by insiders signifies that they have been buying or selling the stock in recent months in anticipation of some upcoming event.
Check Bionik Ownership Details
Bionik Laboratories Corp Risk Profiles
Mean Deviation | 32.78 | |||
Standard Deviation | 129.1 | |||
Variance | 16666.67 | |||
Risk Adjusted Performance | 0.1244 |
Bionik Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Bionik Laboratories without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Sign In To Macroaxis Now
Sign In To MacroaxisSign in to explore Macroaxis' wealth optimization platform and fintech modules |
All Next | Launch Module |
Bionik Laboratories Corporate Management
CPA Russo | CEO Pres | Profile | |
Mark Eiseman | Sales Director | Profile | |
Daniel CPA | Ex CFO | Profile | |
Dan CPA | Ex CFO | Profile | |
John Smathers | Director Operations | Profile |
Other Information on Investing in Bionik Pink Sheet
Bionik Laboratories financial ratios help investors to determine whether Bionik Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bionik with respect to the benefits of owning Bionik Laboratories security.